In response to speculation and stakeholder inquiries, Bayer has publicly disclosed the contents of its private proposal to acquire Monsanto.

Bayer has made an all-cash offer to acquire all of the issued and outstanding shares of common stock of Monsanto Company for USD 122 per share or an aggregate value of USD 62 billion. This offer, based on Bayer’s written proposal to Monsanto dated May 10, 2016, represents a substantial premium of:

• 37 percent over Monsanto’s closing share price of USD 89.03 on May 9, 2016
• 36 percent over the three-month volume weighted average share price
• 33 percent over the six-month volume weighted average share price
• Last twelve months EBITDA multiple of 15.8x as of February 29, 2016

The acquisition of Monsanto would be a compelling opportunity to create a global agriculture leader, while reinforcing Bayer as a Life Science company with a deepened position in a long-term growth industry. The combination is expected to provide Bayer’s shareholders with accretion to core EPS by a mid-single-digit percentage in the first full year after closing and a double-digit percentage thereafter. Initially, Bayer expects annual earnings contributions from total synergies of approximately USD 1.5 billion after year three plus additional integrated offer benefits in future years.

Click here to read the full press release on Bayer.com